Overview

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

Status:
Completed

Trial end date:
2002-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV-induced anemia In HCV-infected subjects.

Phase:

Phase 2

Details

Lead Sponsor:

Ortho Biotech Products, L.P.

Treatments:

Interferons
Ribavirin